Monday, December 11, 2017 11:34:48 AM
5:25 AM ET 12/11/17 | Briefing.com
Co announced data supporting its non-viral approach to rapid manufacture of chimeric antigen receptor (CAR)-modified T cells to treat patients with cancers Two trials demonstrated that first-generation SB-modified CD19-specific CAR+ T cells appear to provide long-term cancer control when infused after hematopoietic stem-cell transplantation (HSCT) for patients with advanced CD19+ malignancies and could be detected years after administration in some recipients. All seven patients with advanced CD19+ non-Hodgkin's lymphoma (NHL) that received autologous T cells were alive at a median survival of 40 months since infusion, with progression-free survival (PFS) reported at 86% and overall survival (OS) at 100%. For 19 patients with advanced CD19+ acute lymphoblastic leukemia (ALL) and NHL infused with allogeneic T cells following HSCT, nine patients were alive with a median survival of 31 months. The PFS rate and OS rates are 32% and 49%, respectively. Of the subset of eight patients who received donor-derived T cells after haploidentical HSCT, PFS and OS rates are 50% and 63%, respectively. Persistence of circulating SB-modified CAR+ T cells was demonstrated at two years in an autologous and allogeneic patient and for four years in two autologous patients.
Recent TCRT News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:46:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:44:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:05:27 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:43:20 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:58:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:45:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:47:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:30:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:30:50 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:25:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:00:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 01:00:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 12:30:01 PM
- Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives • GlobeNewswire Inc. • 11/14/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 08:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2023 09:34:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/01/2023 04:20:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:37:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:16:29 PM
- Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives • GlobeNewswire Inc. • 08/14/2023 08:05:34 PM
- Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies • GlobeNewswire Inc. • 06/29/2023 11:00:53 AM
- Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 05/25/2023 09:00:52 PM
- Alaunos Therapeutics Reports First Quarter 2023 Financial Results • GlobeNewswire Inc. • 05/10/2023 11:00:17 AM
- Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 • GlobeNewswire Inc. • 05/03/2023 12:30:00 PM
UC Asset Expected to Report $0.03/share Net Profit for 2023 • UCASU • Apr 11, 2024 10:00 AM
Kona Gold Beverages & Apple Rush Co. Execute Joint Venture & Manufacturing Agreement • APRU • Apr 11, 2024 9:40 AM
VAYK Confirmed Its Eligibility for $1.8 Million Investment through Federal EB5 Program • VAYK • Apr 11, 2024 9:00 AM
ILUS Moves Forward With Its Two Subsidiary Uplists and Equity Dividend • ILUS • Apr 10, 2024 9:36 AM
Quartz Intersects 102m of 2.22 g/t Au and 104 g/t Ag Announces New Discovery at Prodigy on its Maestro Project, British Columbia • QZM • Apr 10, 2024 8:00 AM
Swifty Global Announces Record Annual Results Ahead of National Exchange Reverse Merger • DRCR • Apr 9, 2024 1:55 PM